Division of Nestle SA
Latest From Galderma SA
A group of investors has bought Nestlé Skin Health, renamed it Galderma to capitalize on its legacy in dermatology and put M&A veteran, former Shire CEO Flemming Ornskov, at its helm.
Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing use in adolescents as well as in adults, and positive Phase III results in children aged six to 11 years with severe atopic dermatitis, should help.
New OTC medicines for fungal nail infections and verrucas have been launched in the UK by Galderma, Reckitt Benckiser and Vemedia, while new foot-care products have also been introduced by Blistex, Epitact and Dermatonics.
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.
- OTC, Consumer
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Nestle SA
- Senior Management
Flemming Ornskov, MD, CEO
Thomas Dittrich, CFO
Cecile Dussart, VP, Head of Operations
- Contact Info
Phone: (33) 21 642 78 00
Avenue Gratta-Paille 2
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.